Novartis 披露 Zolgensma 新增七例肿瘤报告
STAT+: Amgen’s Repatha linked to fewer heart attacks
Novartis 披露 Zolgensma 自 2019 年获批以来新增七例肿瘤报告,总计九例。这些报告可能影响该基因疗法的安全性评估。
Novartis cites more tumor reports, PhRMA’s big spending on search ads, and more biotech news
![]()
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pithy intro text about the biopharma milieu.
Novartis cites more tumor reports after Zolgensma
Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy for spinal muscular atrophy. The company has received nine tumor reports in all since the treatment was approved in 2019, STAT’s Ed Silverman and Jason Mast write.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Biotech Correspondent
Meghana Keshavan covers biotech and contributes to The Readout newsletter.
来源:STAT 主站 · statnews.com